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shortly after acute vascular events. 13 Increased copeptin levels were found in patients with acute myocardial infarction even when troponin T was still negative. 14 In combination with highsensitive troponin T, copeptin has valid properties ruling-out acute myocardial infarction 15 and thereby, helps to identify patients with chest pain who can be discharged home from the emergency department without increased risk for major adverse coronary events. 16 In this study, we assessed copeptin levels in a prehospital setting of hyperacute stroke care on a specialized stroke ambulance and examined its value in discriminating between strokes and stroke mimics as well as between vascular and nonvascular diagnoses.
Methods Patients
The Pre-Hospital Analysis and Triage of Acute Stroke and Stroke Like Syndromes With Biomarkers study (PHANTAS-B) was conducted as a parallel study of the Pre-Hospital Acute Neurological Therapy and Optimization of Medical Care in Stroke Patients study (PHANTOM-S) that investigated the effects of a specialized Stroke Emergency Mobile Unit on hyperacute treatment in patients with stroke. 17 The study was integrated in the emergency medical system of Berlin, Germany (NCT01382862). 18 Stroke Emergency Mobile was deployed by the dispatch center when a previously validated stroke identification algorithm indicated a suspected acute stroke. 19 The stroke identification algorithm at the dispatch center had demonstrated a sensitivity of 53% for stroke and a positive predictive value of 59% for stroke and transient ischemic attack. Between June 2011 and May 2013, we included consecutive patients with informed consent who received Stroke Emergency Mobile care. Discharge diagnoses were collected from all participating hospitals. Vital status and modified Rankin Scale score at 3 months was collected in ischemic stroke patients with thrombolytic treatment.
Blood Sampling and Analysis
Blood samples were taken immediately after arrival at scene before any treatment was administered. They were centrifuged with 3000×g for 15 minutes. Centrifugation was performed referring to a standardized clinical protocol. The reliability of this procedure conforms to plasma isolated in a laboratory. After filling in a cryotube, plasma samples were stored at 4°C in the ambulance. After arriving at the emergency medical system station (maximum 8 hours after sampling), they were frozen at −20°C. Frozen samples were shipped to the core laboratory facility of ThermoFisher Biomarkers (Thermo Fisher Scientific, Clinical Diagnostics, BRAHMS GmbH, Hennigsdorf, Germany) for analysis in a blinded and randomized fashion. Copeptin was measured from EDTA plasma using the BRAHMS copeptin us KRYPTOR immunofluorescent assay with an analytical detection limit of <1 pmol/L and a functional assay sensitivity of 1.8 pmol/L. The direct detection range was 1.8 to 500 pmol/L and the extended, involving automatic dilution, was ≤2000 pmol/L. Copeptin levels of individual patient samples were measured in single determinations. In case determined levels were below the functional assay sensitivity, conformational determinations were performed. Repeated measurements confirmed initial determinations with a coefficient of variation of 5%.
Documentation of Clinical Data
We used the data of the PHANTOM-S study. Time of symptom onset, time of blood sampling, clinical symptoms, results of computed tomographic imaging, and point of care laboratory in the ambulance were documented in the onsite Stroke Emergency Mobile documentation system. Final diagnoses of acute in-hospital care were collected as International Classification of Diseases, Tenth Revision (ICD-10) codes from all hospitals that participated in the PHANTOM-S study. Copeptin laboratory results were merged with clinical data using pseudonyms.
Categorization of Hospital Diagnoses
The following ICD-10 codes were categorized as acute cerebrovascular events: G45.x (except G45.4), I60.x I61.x, I63.x, I64.x. Other neurological diagnoses that lead to emergency care and hospital admission were classified as stroke mimics including the following ICD-10 codes: A8.x, A35.x, C70.x, C71.x, C72.x, F0.x, F1.x, G0.x, G1.x, G2.x, G5.x, G6.x, G7.x, G8.x, G9.x, G30.x, G31.x, G32.x, G35.x, G36.x, G40.x, G41.x, G42.x, G43.x, G44.x, G45.4x, G47.x, G48.x, H34.x, H46.x, H48.x, H49.x, H50.x, H51.x, H52.x, H53.x, H54.x, H81.x, I62.x, I69.x, R4.x, R25.x, R26.x, R27.x, R28.x, R29.x, R55.x, S0.x, T3.x, T4.x, T5.x, T60.x, T61.x, T62.x, T63.x, T64.x, T65.x. Vascular diseases comprised the following ICD-10 codes: D65.1x, D68.3x, G45.x (except G45.4), G46.x, H34.x, I6.x, I20.x, I21.x, I22.x, I23.x, I24.x, I26.x, I60.x, I61.x, I63.x, I64.x, I65.x, I66.x, I67.x, I68.x, I69.x, I71.0x, I71.1x, I71.3x, I71.5x, I71.8x, I72.x, I74.x, I77.2x, K55.0x, R02.x, and R04.x. All other ICD-10 codes were classified as nonvascular events. For description of the diagnostic spectrum, we categorized the diagnosis in diagnostic subgroups (Table 1; Table I in the online-only Data Supplement). Noncerebrovascular diagnoses (non-CVDs) that were coded in 1 patient only were subsumed under other non-CVDs. 
Statistical Analysis
We used the Mann-Whitney U test for comparisons of copeptin levels in the different diagnostic categories, and vital status at 3 months. For graphical and statistical comparisons of copeptin levels, we performed a logarithmic transformation (log 10) to reduce skewness. A P<0.05 was considered as statistically significant. For comparison of copeptin levels and time to taking blood samples, we used the following categories: 15-30 minutes, 31-60 minutes, 61-90 minutes, 91-120 minutes, 121-180 minutes, and >180 minutes. We used the Spearman correlation test for comparison of copeptin levels with times to blood sampling, NIHSS and age, and illustrated copeptin levels in different time and NIHSS categories. Good outcome was defined as a modified Rankin Scale score ≤1 and bad outcome as a modified Rankin Scale score >1. The odds for good and bad outcome according to copeptin levels were calculated and were adjusted for NIHSS and age. Statistical analyses were performed in SPSS version 22.
Ethics Approval
The study was approved by the Data Protection Commissioner and the Ethics Committee of the Charité Universitätsmedizin Berlin. Documentation was done with pseudonyms. Data were analyzed only if patients or legally authorized representatives had given informed consent on the use of individual blood material and clinical data.
Results
From June 2011 to May 2013, we collected samples from a total of 576 patients. Fifteen patients had to be excluded because of missing information about final diagnosis. Copeptin levels (pmol/L) according to diagnoses are shown in Table 1 . Diagnostic categories according to ICD-10 codes are shown in Table I in the online-only Data Supplement. Table 2 shows patient characteristics of vascular and nonvascular patients. Characteristics of stroke and stroke mimic patients are shown in Table 3 . We compared copeptin levels of cerebrovascular (n=383) patients (ischemic stroke, hemorrhagic stroke, transient ischemic attack, and non-specified cerebrovascular diseases) with levels of stroke mimic patients (n=90; Figure 1) . In a second analysis, we compared copeptin levels of vascular patients (n=391) and levels of nonvascular patients (n=170; Figure 1 ). We found no significant differences in copeptin levels neither between stroke and stroke mimic patients (P=0.15) nor between ischemic and hemorrhagic stroke patients (P=0.60) nor between vascular and nonvascular patients (P=0.57). Only 5 patients died during in-hospital stay. They had nonsignificantly higher copeptin levels compared with surviving patients 
15).
The 3-month survival status of patients with ischemic stroke was collected from 159 patients. We examined the prognostic value of copeptin and compared copeptin levels of surviving (n=151) and nonsurviving (n=8) patients. These 8 nonsurviving patients include the 5 patients, who died during in-hospital stay. Significantly higher copeptin levels in nonsurviving patients (median, 27.4 pmol/L; IQR, 20.2-54.7 pmol/L) were found compared with surviving patients (median, 11.7 pmol/L; IQR, 5.2-30.9 pmol/L; P=0.024). However, stroke severity (NIHSS, 18.5 versus 6.0; P<0.001) and age (83.0 versus 73.0 years; P=0.008) were also significantly higher in nonsurviving patients compared with surviving patients. Modified Rankin Scale score was available in 141 patients. Logarithmic transformed copeptin levels were not an independent predictor for bad outcome (odds ratio, 0.74; 95% confidence interval, 0.40-1.45; P=0.41). There was no association between time from symptom onset and copeptin levels neither for all patients (Spearman ρ, 0.007) nor for the subgroup of patients with ischemic stroke (Spearman ρ, −0.024; Figure 2 ). There were significantly higher levels of copeptin in patients with higher stroke severity (NIHSS 0 There was no significant association between copeptin levels and age (Spearman ρ, 0.074; P=0.23).
Discussion
In our study, copeptin levels obtained before hospital arrival did neither discriminate between stroke and stroke mimic patients nor between vascular and nonvascular patients. As copeptin elevation seems to relate to the severity of stroke or of other cardiovascular events, 7 we had assumed that it might also discriminate between stroke and stroke mimics as well as between vascular and nonvascular events. Contrary to these considerations, our results did not show significant differences in copeptin levels between these groups of patients. Copeptin was elevated within the first minutes after the event, but there was no correlation between copeptin levels and time from symptom onset to drawing blood samples. Higher copeptin levels were associated with increased mortality in patients with stroke in unadjusted analysis. As we could not perform multivariable regression for the small event rate, we cannot conclude that high copeptin levels have an independent prognostic value. Nevertheless, the prognostic value for patients with stroke is in line with previous observations 7,9-11 and a recently published study showing an association of copeptin with stroke occurrence after transient ischemic attack. 20 The prognostic property of copeptin with regard to mortality and morbidity was also shown in patients with other cardiovascular events. 4, 21, 22 In our analysis, copeptin elevation occurred in a wide range of diagnoses, most likely induced by an activation of the endogenous stress system. Previous studies found an elevation in other nonvascular diseases, too. 23, 24 Copeptin is released rapidly after hemodynamic stress. 13, 14 In our patients, we found no influence of the interval from symptom onset to blood sampling on copeptin levels. Although we cannot rule out that copeptin was elevated before the event, this result suggests an immediate secretion, within the first minutes after developing symptoms. Therefore, copeptin is obviously not an appropriate marker to indicate time to stroke onset. Strengths of our study are the relatively high number of patients as well as the very early examination on an ambulance. To our knowledge, it is the first study that examined copeptin as a potential biomarker for discrimination between strokes and stroke mimics in the prehospital setting. Although the statistical results of our study were negative, we have shown that prospective blood sampling, and centrifugation and biomarker research are feasible in the prehospital setting without causing time delays in patient care. A limitation of the study is the unequal distribution of differential diagnoses. The PHANTOM-S study was focused on patients with stroke. As a consequence, the number of nonvascular patients was smaller than the number of vascular patients. Furthermore, we collected information about vital status at 3 months in patients with ischemic stroke only because the aim of our study was not an outcome analysis and the study methodology did not allow the collection of longterm outcome in other patients groups.
Conclusions
Copeptin is released at an early stage after onset of acute diseases. In our study, it did not discriminate between strokes and stroke mimics or between vascular and nonvascular diseases in the prehospital setting.
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